3D Systems stands at the midpoint of a transformation it is financing out of its own balance sheet. The company that invented stereolithography has spent the last three years in a long bleed. Revenue fell by a tenth or more in the fiscal year 2025, and the business posted operating losses in each of the two prior years, while shareholders absorbed a large goodwill impairment in the Healthcare unit in late 2024. Yet the second quarter of 2026, reported in early August, marks an inflection the filings now document in concrete terms. Revenue held flat on the year but rose modestly excluding the software divestitures, and adjusted EBITDA climbed from a clear loss to a near-breakeven number, with the first half of 2026 already posting a small positive figure.
The counterweight is real. The same quarter still produced a GAAP net loss, disclosure controls were certified as not effective because of two material weaknesses, operating cash flow remained negative for the half, and a secured convertible note due 2030 sits behind a covenant requiring a minimum cash balance. Then there is the human element. One day after the print, the board announced that Dr. Jeffrey Graves, the president and chief executive officer who has run the company since 2020, steps down and retires from the board, with a successor search already under way. The investment question is whether the cost cuts and the four high-growth priority markets can compound fast enough to outrun the debt, the dilution, and the executive vacuum. The stock, after a five-year collapse, now embeds a bet on that inflection.